|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
intravenous injection
|
|
gptkbp:approves
|
gptkb:2010
gptkb:FDA
|
|
gptkbp:atccode
|
L01 CD04
|
|
gptkbp:brand
|
gptkb:Halaven
|
|
gptkbp:casnumber
|
680047-69-0
|
|
gptkbp:chemical_formula
|
C17 H21 Br N2 O4
|
|
gptkbp:clinical_trial
|
Phase III
NCT00629278
NCT01337765
NCT02016239
NCT02208491
NCT02400000
|
|
gptkbp:clinical_use
|
metastatic breast cancer
metastatic liposarcoma
|
|
gptkbp:contraindication
|
hypersensitivity
severe liver impairment
|
|
gptkbp:developed_by
|
spongistatin
|
|
gptkbp:discovered_by
|
gptkb:Eisai_Co.,_Ltd.
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:financial_stability
|
stable for 24 hours at room temperature
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
eribulin
|
|
gptkbp:indication
|
second-line treatment
third-line treatment
|
|
gptkbp:invention
|
patented
|
|
gptkbp:lifespan
|
40 hours
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Japan
gptkb:USA
|
|
gptkbp:mechanism_of_action
|
microtubule dynamics inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
vial
|
|
gptkbp:pdbid
|
not available
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
NCCN guidelines
|
|
gptkbp:requires
|
available
|
|
gptkbp:research_status
|
ongoing studies
|
|
gptkbp:route_of_administration
|
IV
|
|
gptkbp:service_frequency
|
once every 21 days
|
|
gptkbp:side_effect
|
fatigue
nausea
constipation
peripheral neuropathy
hair loss
neutropenia
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
cancer cells
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:weight
|
373.27 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Halaven
|
|
gptkbp:bfsLayer
|
6
|